Menu
Search
|

Menu

Close
X

Aurinia Pharmaceuticals Inc AUPH.OQ (NASDAQ Stock Exchange Global Market)

5.60 USD
+0.14 (+2.56%)
As of 2:29 AM IST
chart
Previous Close 5.46
Open 5.50
Volume 160,574
3m Avg Volume 215,331
Today’s High 5.66
Today’s Low 5.48
52 Week High 10.54
52 Week Low 3.23
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.71 Mean rating from 7 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Richard Glickman
Executive Chairman of the Board, Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Dennis Bourgeault
Chief Financial Officer, Corporate Secretary, Since 2011
Salary: $228,333.00
Bonus: $150,000.00
Michael Martin
Chief Operating Officer, Since 2014
Salary: $269,167.00
Bonus: $135,626.00
Neil Solomons
Chief Marketing Officer, Since 2013
Salary: $310,000.00
Bonus: $149,250.00
Celia Economides
Associate Vice President, Corporate Communications & Patient Advocacy, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1203-4464 Markham St
VICTORIA   BC   V8Z 7X8

Phone: +1250.7084272

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

SPONSORED STORIES